Thyroid cancer · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Sorafenib monotherapy Variant #04 | — | R 37 339 | 28d | ~10.8 mo | — | ~12 | ~R 448 066 PFS proxy · indirect | 1 |
Axitinib monotherapy Variant #01 | — | R 21 402 | 28d | ~9.2 mo | ~20.9 mo | ~11 | ~R 235 420 PFS proxy · indirect | 4 |
Doxorubicin monotherapy Variant #10 | — | R 1 293 | 21d | ~6.0 mo | ~8.2 mo | ~9 | ~R 11 639 PFS proxy · indirect | 18 |
Selpercatinib monotherapy Variant #01 Partial | RET | — | 28d | — | — | — | — | 1 |
Pralsetinib monotherapy Variant #01 Partial | RET | — | 28d | — | — | — | — | — |
5 of 5 regimens shown